Thursday, April 02, 2026 12:58:14 PM
I see a developmental biotech that had zero value when Missling took over and was close to bankruptcy.
I see a company that has a drug pipeline with several candidates. I see a company that has had two trials that were close but were not approved. The decisions that that resulted in trials failure were made 7 years ago. The company has learned a lot since then.
I see a company with no debt and a moderate share count.
I see great long term potential in this company. I see a short term share price that is slightly below my cost basis.
I see that bringing a drug to market is a difficult task and many developmental biotech companies fail in the attempt and die.
I see Anavex having the resources to continue to pursue drug approval for 2-73 and 3-71 in spite of the recent rejection by the EMA.
Do like to be down on my investment in Anavex at the current share price? No. No one likes setbacks. Do I still think that Anavex will succeed? Yes.
The FDA has yet to weigh in on the present P2/3 trial. Worst case another P3 trial will be required.
There are other trials that Anavex will be running. Some shorter in duration than what will be required for AD.
I see the situation from a longer term perspective than many.
Short term the situation sucks. That's the way things sometimes go. YMMV
I see a company that has a drug pipeline with several candidates. I see a company that has had two trials that were close but were not approved. The decisions that that resulted in trials failure were made 7 years ago. The company has learned a lot since then.
I see a company with no debt and a moderate share count.
I see great long term potential in this company. I see a short term share price that is slightly below my cost basis.
I see that bringing a drug to market is a difficult task and many developmental biotech companies fail in the attempt and die.
I see Anavex having the resources to continue to pursue drug approval for 2-73 and 3-71 in spite of the recent rejection by the EMA.
Do like to be down on my investment in Anavex at the current share price? No. No one likes setbacks. Do I still think that Anavex will succeed? Yes.
The FDA has yet to weigh in on the present P2/3 trial. Worst case another P3 trial will be required.
There are other trials that Anavex will be running. Some shorter in duration than what will be required for AD.
I see the situation from a longer term perspective than many.
Short term the situation sucks. That's the way things sometimes go. YMMV
Success is the best revenge.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
